Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2020-11-09
2025-02-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EDoF IOLs vs Monofocal IOL
NCT03172351
Intraindividual Comparison of EMO IOLs
NCT05822089
Bilateral Monofocal Versus Monofocal-EDOF IOL Implantation: Quality of Vision Comparison
NCT06002399
Evaluation Of Patient Satisfaction And Quality Of Vision After EDOF Or Trifocal IOL Implantation
NCT07295119
Low-add Multifocal vs. Monofocal IOLs
NCT03749161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Edof IOL vs. multifocal IOL I
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm one (I) participants will receive Edof IOL one (I) vs. multifocal IOL one (I).
phacoemulsification and intraocular lens implantation
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
intraocular lens implantation
intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
Edof IOL vs. multifocal IOL II
The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. In Arm two (II) participants will receive Edof IOL one (I) vs. multifocal IOL two (II).
phacoemulsification and intraocular lens implantation
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
intraocular lens implantation
intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
phacoemulsification and intraocular lens implantation
bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
intraocular lens implantation
intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 50-90
* Visual potential in both eyes of 20/30 or better as determined by investigators estimation
* Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Exclusion Criteria
* Relevant other ophthalmic diseases (such as retinal degenerations, etc.)
* Uncontrolled systemic or ocular disease
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christina Leydolt
Assoc. Prof. PD Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Vienna
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1163/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.